ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 17,900 shares, a drop of 63.9% from the August 31st total of 49,600 shares. Currently, 1.7% of the company’s shares are short sold. Based on an average daily volume of 145,600 shares, the short-interest ratio is presently 0.1 days.

ZyVersa Therapeutics Stock Up 1.4 %

Shares of ZyVersa Therapeutics stock opened at $2.19 on Wednesday. The firm’s 50 day moving average price is $3.02 and its 200-day moving average price is $4.71. ZyVersa Therapeutics has a 52-week low of $2.08 and a 52-week high of $62.30.

ZyVersa Therapeutics (NASDAQ:ZVSA) last released its earnings results on Friday, August 9th. The company reported ($3.31) EPS for the quarter, topping analysts’ consensus estimates of ($5.20) by $1.89. On average, equities research analysts forecast that ZyVersa Therapeutics will post -22.7 EPS for the current fiscal year.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.